
“EarlyCDT-Lung, designed for the early detection of lung cancer, is the first autoantibody panel assay to be released successfully on to the US market. Oncimmune®, the company who designed and commercialised this test, intends to release a similar autoantibody panel assay for early detection of breast cancer in high risk women in the near future, followed by similar tests for other solid tumours (eg colon, liver, ovary, stomach, etc). The development and validation strategy described here for EarlyCDT-Lung would also apply to similar tests for other tumour types subject to the basic rules of a good screening test being adhered to, these being; that it is reasonably simple to perform, highly robust, reproducible and will be cost-effective in production and in the market place.”